Recombinant Human LILRB4 / CD85k / ILT3 Protein, His Tag (SPR verified), 100 µg

Background
Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Source
Recombinant Human LILRB4, His Tag (LI4-H52H7) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - Glu 259 (Accession # AAH26309.1).
Predicted N-terminus: Gln 22

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 28.2 kDa. The protein migrates as 32-43 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Identification of actionable targets for breast cancer intervention using a diversity outbred mouse model"
Jacob, Wei, Bepler et al
iScience (2023) 26 (4), 106320
(2) "Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets"
Morse, Rios, Ye et al
Expert Opin Investig Drugs (2023) 32 (2), 107-125
(3) "Comprehensive analysis of LILR family genes expression and tumour-infiltrating immune cells in early-stage pancreatic ductal adenocarcinoma"
Gao, Mo, Han et al
IET Syst Biol (2023)
Showing 1-3 of 201 papers.